Long-term Iron Needs of Renal Transplant Recipients

肾移植受者的长期铁需求

• 批准号: 6932134
• 负责人: MORTEZA JANGHORBANI
• 金额: $ 19.92万
• 依托单位: BIOCHEMANALYSIS CORPORATION
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-09-01 至 2008-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6932134
• 关键词: ascorbate; clinical research; diet therapy; dietary iron; dietary supplements; gastrointestinal absorption /transport; human subject; human therapy evaluation; kidney transplantation; microcytic /hypochromic anemia; nutrition related tag; oral administration; patient oriented research; therapy design /development

DESCRIPTION (provided by applicant): The long-term objectives of this project are to: (a) Formulate an oral iron/ascorbic acid supplement specific to the needs of renal transplant recipients (RTxRs), (b) evaluate the efficacy of oral iron/ascorbic acid supplementation to meet the iron needs of this patient population as part of their routine post-transplant (post-Tx) care, and (c) establish a consulting service to work in collaboration with transplant/nephrology centers. Many RTxRs are at risk for iron-deficiency anemia. Most because they have absolute iron deficiency (AID) although some have relative iron deficiency (RID). An effective strategy to identify and treat post-transplant anemia (PTA) currently does not exist and its development necessitates insight into factors that affect iron absorption and utilization in RTxRs. We have recently developed a noninvasive method that permits evaluation of the efficacy of iron absorption/utilization. Our method is based on oral administration of a known amount of stable-isotope-labeled iron (58Fe), and the nonabsorbable marker DyCl3, followed by laboratory analysis of the ratio 58Fe -Excess/Dy in one or two stool samples and 58Fe -Excess in a blood sample obtained two weeks later. We propose to investigate factors that affect iron status of RTxRs and how to provide iron for their erythropoietic needs as part of their long-term care. During Phase-I, we will establish the feasibility of our overall strategy for meeting the iron needs of RTxRs by demonstrating that absorption/utilization of iron from low-dose ferrous ascorbate is sufficiently high throughout the post-Tx period in patients with AID to permit its use for this purpose. During Phase- IE, we will investigate parameters of iron supplementation-dose, frequency, most effective formulation of iron plus ascorbate - that are important for development of an effective strategy and in relation to issues such as immunosuppressive therapy.

描述（由申请人提供）：该项目的长期目标是：(a)制定针对肾移植受者（RTxRs）需求的口服铁/抗坏血酸补充剂，(b)评估口服铁/抗坏血酸补充剂的功效，以满足该患者群体的铁需求，作为其常规移植后（post-Tx）护理的一部分，(c)建立与移植/肾病中心合作的咨询服务。许多rtxr存在缺铁性贫血的风险。大多数是因为他们有绝对缺铁（AID），尽管有些人有相对缺铁（RID）。目前尚不存在识别和治疗移植后贫血（PTA）的有效策略，其发展需要深入了解影响rtxr铁吸收和利用的因素。我们最近开发了一种非侵入性方法，可以评估铁吸收/利用的功效。我们的方法是口服一定量的稳定同位素标记的铁（58Fe）和不可吸收的标记物DyCl3，然后在实验室分析一或两个粪便样本中的58Fe -Excess/Dy比率，以及两周后获得的血液样本中的58Fe -Excess。我们建议研究影响rtxr铁状态的因素，以及如何为他们的红细胞生成需求提供铁，作为他们长期护理的一部分。在i期，我们将通过证明低剂量抗坏血酸亚铁对铁的吸收/利用在整个治疗后期间足够高，从而确定我们满足RTxRs铁需求的总体策略的可行性，从而允许AID患者将其用于此目的。在IE阶段，我们将研究补铁的参数——剂量、频率、铁加抗坏血酸的最有效配方——这对制定有效策略和免疫抑制治疗等问题很重要。